Miguel Ángel
Álvarez de Mon González
Profesor/a Asociado/a
Hospital Universitario de Guadalajara
Guadalajara, EspañaHospital Universitario de Guadalajara-ko ikertzaileekin lankidetzan egindako argitalpenak (9)
2023
-
Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer
Journal of Personalized Medicine, Vol. 13, Núm. 2
2022
-
Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer
Cancers, Vol. 14, Núm. 8
-
Implication of ERBB2 as a Predictive Tool for Survival in Patients with Pancreatic Cancer in Histological Studies
Current Oncology, Vol. 29, Núm. 4, pp. 2442-2453
-
Modification of the Polymer of a Bone Cement with Biodegradable Microspheres of PLGA and Loading with Daptomycin and Vancomycin Improve the Response to Bone Tissue Infection
Polymers, Vol. 14, Núm. 5
-
Oxidative Stress Markers Are Associated with a Poor Prognosis in Patients with Pancreatic Cancer
Antioxidants, Vol. 11, Núm. 4
-
Patients with Invasive Lobular Carcinoma Show a Significant Increase in IRS-4 Expression Compared to Infiltrative Ductal Carcinoma—A Histopathological Study
Medicina (Lithuania), Vol. 58, Núm. 6
-
Prognostic role of IRS-4 in the survival of patients with pancreatic cancer
Histology and histopathology, Vol. 37, Núm. 5, pp. 449-459
-
Understanding the basis of major depressive disorder in oncological patients: Biological links, clinical management, challenges, and lifestyle medicine
Frontiers in Oncology, Vol. 12
2021
-
Towards an updated view on the clinical management of pancreatic adenocarcinoma: Current and future perspectives (Review)
Oncology Letters, Vol. 22, Núm. 5